Biocon block deal 2026: Mylan sells 5.64% at 8% discount

Biocon set for Mylan’s full exit via July 14 block deal

Biocon Ltd is expected to remain in focus after Mylan Inc, an arm of US healthcare major Viatris, initiated a block deal to sell its entire holding in the company. The offer involves a complete exit of Mylan’s 5.64% stake, ending a long-standing shareholding relationship. Market participants will track the demand for the shares, the final clearing price, and any near-term impact on Biocon’s trading.

The development comes with specific deal terms already outlined in market documents and media reports. The key points include the number of shares on offer, the floor price, the discount to the prevailing market price, and the expected trade and settlement dates. Biocon’s stock had already seen price action ahead of the transaction, closing lower on the BSE in the session referenced.

What Mylan is selling and how big the deal is

According to sources, Mylan is offering around 9.2 crore shares in Biocon through the block deal. A Mint term sheet described the proposed sale as 92 million equity shares, representing 5.64% of Biocon’s existing equity. The transaction size has been reported at around ₹3,500 crore, while the term sheet pegged it at up to $163 million (₹3,481 crore).

This is a minority stake sale but large enough to matter for near-term liquidity and trading volumes. A block deal of this scale typically draws institutional participation due to the size and the structured execution window. The deal also marks a clean end to Mylan’s equity presence in Biocon, rather than a partial reduction.

Floor price and the implied discount

The floor price has been set at ₹378.50 per share. Reports said this represents about an 8% discount to the then-current market price, with Mint noting a 7.9% discount to Biocon’s closing price on the NSE on 13 July.

The discount is a key element for investors evaluating whether to participate. It reflects how sellers in block trades often price shares to ensure adequate demand for a large one-time supply. For existing shareholders, the floor price and the final discovery price are closely watched because they can influence near-term sentiment and market positioning.

Offer window, trade date, and settlement

The term sheet reviewed by Mint indicated the offer opened on 13 July and will close on 14 July. The trade is expected to take place on 14 July, with settlement scheduled for 15 July. These dates matter because the execution and settlement timeline can shape short-term flows and delivery positions.

The block deal is being managed by Jefferies and Citi as joint bookrunners, according to the same term sheet. Bookrunners typically coordinate with potential institutional buyers, manage the order book, and help the transaction clear within the specified window.

Why Mylan owned Biocon shares

Mint reported that Mylan acquired the stake after Biocon completed its acquisition of Mylan’s holding in Biocon Biologics in January 2026 through a combination of a share swap and cash consideration. That transaction history provides context for how a strategic counterparty ended up with an equity position in Biocon Ltd.

Separately, Biocon had disclosed that it completed the acquisition of remaining equity shares of its unlisted material subsidiary, Biocon Biologics Ltd, from Mylan for a cash consideration of $100 million. The acquisition referenced a broader board-approved plan announced on 6 December 2025, under which Biocon agreed to acquire 14.37 crore equity shares of Biocon Biologics from various investors, including Mylan, for an aggregate consideration of $100 million.

Biocon share move ahead of the block deal

Biocon’s shares on Monday settled at ₹410.55 apiece on the BSE, down 1.89% compared with the previous close. Over the same session, the benchmark Sensex settled marginally higher with 0.06% gains. The stock’s move relative to the index will be monitored as the block deal proceeds, especially given the announced discount to the market price.

The combination of a large secondary sale and a discounted floor price can put focus on near-term supply, even if the underlying transaction is a shareholder-level exit rather than a primary issuance by the company. Investors also tend to track whether the shares are absorbed smoothly by institutions.

Key facts at a glance

Capital raising and transaction backdrop

Biocon has also used institutional fund-raising routes in the recent past. A company statement dated January 14, 2026 said Biocon completed a Qualified Institutions Placement (QIP) of ₹4,150 crore, issuing 112,664,585 equity shares at ₹368.35 per share. The company stated the proceeds would be used primarily to meet the cash consideration payable to Mylan for buying out its shareholding in Biocon Biologics, including repayment of debt availed in that regard.

The provided timeline also referenced another QIP event, noting that Biocon concluded a ₹4,500 crore equity fundraise through a QIP on 20 June. These transactions help explain why Mylan-related payments and stake changes have featured prominently in Biocon’s corporate actions and market narratives in 2025-26.

Market impact and what investors will track

The immediate market relevance is straightforward: a large shareholder is selling its full stake through a structured block deal with a stated floor price. The transaction size, the number of shares, and the discount to the traded price can influence short-term trading dynamics. Investors will watch whether the deal clears near the floor price or at a tighter discount, which can indicate the strength of institutional demand.

They will also track trading volumes and price moves around 14 July, when the trade is expected to take place, and on 15 July, when settlement is scheduled. Since the deal represents a full exit by Mylan, the overhang from this specific shareholder is expected to end once the transaction completes.

Why this event matters

A full exit by a long-time shareholder is a notable governance and ownership change even when it does not directly alter company operations. The block deal is also significant because it follows a period in which Biocon’s transactions with Mylan were linked to the consolidation of Biocon Biologics and related funding actions.

The pricing mechanics add another layer of focus. With a floor price of ₹378.50 versus a BSE close of ₹410.55 in the referenced session, the discount is material and becomes a visible benchmark for the market. Whether the shares are absorbed cleanly can influence short-term sentiment, even though the sale is not a reflection of new financial guidance from Biocon.

Conclusion

Mylan’s plan to sell its entire 5.64% stake in Biocon through a block deal on July 14 is set to be one of the key market events for the stock. The transaction, reported at around ₹3,500 crore and priced with a ₹378.50 floor, is designed to complete Mylan’s exit from the biotechnology company. The next confirmed milestones are the close of the offer on 14 July, execution expected the same day, and settlement scheduled for 15 July.